DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

57.48 -0.86 (-1.47%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MRK $57.48 -1.47%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $58.19
Previous Close $58.34
Daily Range $57.48 - $58.31
52-Week Range $52.49 - $63.62
Market Cap $163.1B
P/E Ratio 14.33
Dividend (Yield) $1.80 (3.1%)
Ex-Dividend Date
Dividend Pay Date
Volume 10,458,436
Average Daily Volume 11,685,287
Current FY EPS $3.40




Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website:

News & Commentary

Why It's Not Too Late to Buy Agenus, Inc. Stock

Small-cap biotech Agenus has seen its share price roar higher since acquiring some highly prized assets in immuno-oncology. Here's why this stock could push even higher going forward.

Merck’s Keytruda Is Ahead, But Bristol-Myers’ Squibb’s Opdivo Could Catch Up

The Single Worst Practice of the Drug Industry

Pay for delay is a legal maneuver Big Pharma uses to keep generic drugs off the market. According to the FTC, it costs consumers and taxpayers $3.5 billion every year.

OncoSec Medical Has A Promising Technology

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

Merck: Buyback Plan Not As Impressive As It Appears

Out of 12 Big Pharma Stocks, This is the 1 You Can Confidently Hold for the Next 10 Years

Big Pharma stocks often have deep product pipelines, substantial cash flow, and healthy dividends, but they are far from created equal. With patent expirations taking their toll, this would appear to be the one Big Pharma stock you can trust over the next decade.

Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog

Is This Tiny Biotech Still a Buy at All-Time Highs?

Repligen may not be on your watchlist, but it has been (very) good to investors in recent years. Will the ride continue?

Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog

See More MRK News...

MRK's Top Competitors

MRK $57.48 (-1.47%)
Current stock: MRK
JNJ $100.60 (-0.94%)
Current stock: JNJ
NVS $98.61 (-2.67%)
Current stock: NVS
RHHBY $34.38 (0.50%)
Current stock: RHHBY